# Dysport in Hallux Abducto Valgus (HAV) Phase IIa

> **NCT03569098** · PHASE2 · COMPLETED · sponsor: **Ipsen** · enrollment: 186 (actual)

## Conditions studied

- Hallux Abducto Valgus

## Interventions

- **BIOLOGICAL:** Botulinum toxin type A
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03569098
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2019-12-17
- **Final completion:** 2020-05-22
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2021-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03569098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03569098, "Dysport in Hallux Abducto Valgus (HAV) Phase IIa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03569098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*